Login to Your Account



Onxeo's HCC drug bested by physician's choice in HCC trial

By Michael Fitzhugh
Staff Writer

Tuesday, September 12, 2017

Hopes that Onxeo SA's doxorubicin-loaded nanoparticle, Livatag, would finish a pivotal trial and be ready for filing as a new treatment for challenging cases of hepatocellular carcinoma were dashed as the drug failed to outperform standard-of-care therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription